Angle's Parsortix displays potential use for detection of immunotherapy efficacy

Liquid biopsy company Angle said on Friday that breakthrough research had shown the potential use of Parsortix to assess whether or not patients would respond to immunotherapy.

Angle said a recent study by the University of Crete had shown that Parsortix, its cell separation technology, demonstrated the potential of the system to determine if non-small cell lung cancer patients would benefit from the use of immunotherapy drugs.

The AIM-listed firm stated that the study had combined an assessment of immunotherapy drugs PD-L1 immune checkpoint inhibitors, along with a second immune checkpoint, Indolamine-2,3-dioxygenase, on circulating tumour cells.

Angle added that while multiple CTC systems and approaches were evaluated in the study, only CTC detection using Parsortix was "significantly associated with disease progression".

Founder and chief executive Andrew Newland said: "In addition to our key focus on securing FDA clearance for Parsortix, we are progressing the establishment of clinical laboratories so that we can offer laboratory-developed tests.

"The combination of PD-L1 and IDO assessment using Parsortix opens a major market opportunity for Angle in the key area of cancer immunotherapy, for a test which we can offer from our clinical laboratories."

As of 0920 BST, Angle shares were up 1.48% at 53.18p.